Non-alcoholic Steatohepatitis Biomarkers Market To Reach $5.68 Billion By 2030

Non-alcoholic Steatohepatitis Biomarkers Market Growth & Trends

The global non-alcoholic steatohepatitis biomarkers market size is anticipated to reach USD 5.68 billion by 2030 and expand at a CAGR of 23.3% during the forecast period, according to a new report by Grand View Research, Inc. The rising prevalence of Non-alcoholic Steatohepatitis (NASH), fueled by factors such as obesity and diabetes, is significantly driving the demand for NASH biomarkers. The growing diagnosis of NASH drives the demand for accurate diagnostic tools. In addition, government and healthcare initiatives promoting awareness, early detection, and research funding further accelerate market growth. These efforts are crucial in addressing the growing burden of NASH and improving disease management through biomarker development.

Advancements in diagnostic technologies and an increased focus on early detection drive the growth of the NASH biomarkers market. Innovative noninvasive testing methods such as imaging techniques and blood-based biomarkers enable quicker, more accurate diagnoses. Early detection improves treatment outcomes, fueling demand for advanced biomarkers to monitor disease progression. Hence, the growing emphasis of healthcare systems on early intervention impels market growth, helping provide improved solutions for NASH management.

Growing awareness of NASH is expected to propel the demand for effective biomarkers, leading to significant market growth. Increasing recognition of the disease encourages earlier diagnosis and better disease management. Expanding research and development in the field advances the discovery of novel biomarkers, improving diagnostic precision and treatment strategies. These factors are anticipated to drive the demand for NASH biomarkers, contributing to the market expansion.

 Request a free sample copy or view report summary: Non-alcoholic Steatohepatitis Biomarkers Market Report

Non-alcoholic Steatohepatitis Biomarkers Market Report Highlights

• On the basis of type, the serum biomarkers segment led the market with the largest revenue share of 31.2% in 2024, attributed to their ability to provide non-invasive, cost-effective, reliable diagnostic options.

• The hepatic fibrosis biomarkers segment is projected to grow at the fastest CAGR during the forecast period, fueled by their crucial role in assessing the severity and progression of liver damage.

• On the basis of end use, the pharma & CRO industry segment dominated the market with the largest share in 2024, driven by its critical role in drug development, clinical trials, and biomarker validation.

• The diagnostic labs segment is set to be the fastest-growing segment from 2025 to 2030 due to increasing awareness and the rising demand for early detection and diagnosis.

• North America accounted for the largest share of almost 54% in 2024, owing toits advanced healthcare infrastructure, high awareness of liver diseases, and substantial research investments.

Non-alcoholic Steatohepatitis Biomarkers Market Segmentation

Grand View Research has segmented the global non-alcoholic steatohepatitis biomarkers market based on type, end use, and region:

Non-alcoholic Steatohepatitis Biomarkers Type Outlook (Revenue, USD Million, 2018 - 2030)

• Serum Biomarkers

• Hepatic Fibrosis Biomarkers

• Apoptosis Biomarkers

• Oxidative Stress Biomarkers

• Others

Non-alcoholic Steatohepatitis Biomarkers End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Pharma & CRO Industry

• Hospitals

• Diagnostic Labs

• Academic Research Institutes

Non-alcoholic Steatohepatitis Biomarkers Region Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • U.K.

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of key Players of Non-alcoholic Steatohepatitis Biomarkers Market

• GENFIT

• Prometheus Laboratories

• Siemens Healthineers AG

• BioPredictive

• Quest Diagnostics

• AstraZeneca

• Exalenz Bioscience Ltd (meridian bioscience)

• Labcorp

• Pfizer Inc.

• Bristol-Myers Squibb Company